Tapinarof Cream Safe, Effective for Plaque Psoriasis in Intertriginous Areas
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 25, 2023 -- Vtama (tapinarof) cream is efficacious, safe, and well tolerated for the treatment of plaque psoriasis in sensitive intertriginous areas, according to a study presented at the annual Fall Clinical Dermatology Conference, held from Oct. 19 to 22 in Las Vegas.
In a phase 4 clinical trial, Howard Sofen, M.D., of Dermatology Research Associates in Los Angeles, and colleagues evaluated tapinarof cream, 1 percent, for the once-daily treatment of intertriginous plaque psoriasis among 34 adults.
The researchers found that 82.8 percent of participants achieved an intertriginous Physician Global Assessment (iPGA) score of 0 (clear) or 1 (almost clear) and ≥2-grade improvement from baseline at week 12, the primary end point of the study. Two-thirds of participants (65.5 percent) achieved complete disease clearance (iPGA score of 0) at week 12, with a median time to complete disease clearance of eight weeks. Rapid onset of efficacy was seen with iPGA as early as week 2 and with a median time to iPGA success of six weeks, the secondary end point of the study. By week 4, half of patients achieved itch relief (a clinically meaningful ≥4-point improvement in Peak Pruritus-Numeric Rating Scale score), which increased to 75 percent at week 12. No new safety signals were detected, and the most common adverse reactions included folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.
"The results of this phase 4 study are meaningful because patients that entered this study had suffered with extensive disease, many over 10 years duration. While the rates of disease clearance are impressive, the fast onset of Vtama cream and associated itch relief are particularly noteworthy," Sofen said in a statement. "These data, combined with those of previous studies, further indicate that Vtama cream is a safe and effective treatment for adult patients with intertriginous plaque psoriasis."
The study was funded by Dermavant, the manufacturer of tapinarof.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights
MONDAY, May 13, 2024 -- Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to...
Tobacco Smoking Reduces the Odds of Psoriasis Improvement
WEDNESDAY, April 24, 2024 -- Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced...
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.